JLB & Associates Inc. Has $3.41 Million Position in Agilent Technologies, Inc. (NYSE:A)

JLB & Associates Inc. raised its stake in Agilent Technologies, Inc. (NYSE:A) by 14.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 25,382 shares of the medical research company’s stock after buying an additional 3,169 shares during the quarter. JLB & Associates Inc.’s holdings in Agilent Technologies were worth $3,410,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. McAdam LLC boosted its position in shares of Agilent Technologies by 3.1% during the 3rd quarter. McAdam LLC now owns 2,531 shares of the medical research company’s stock worth $376,000 after acquiring an additional 77 shares in the last quarter. Brown Brothers Harriman & Co. increased its stake in shares of Agilent Technologies by 13.5% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 646 shares of the medical research company’s stock valued at $96,000 after purchasing an additional 77 shares during the last quarter. Rovin Capital UT ADV increased its stake in shares of Agilent Technologies by 1.6% in the 3rd quarter. Rovin Capital UT ADV now owns 5,049 shares of the medical research company’s stock valued at $750,000 after purchasing an additional 81 shares during the last quarter. Integrated Advisors Network LLC raised its holdings in shares of Agilent Technologies by 2.5% during the 3rd quarter. Integrated Advisors Network LLC now owns 3,582 shares of the medical research company’s stock worth $532,000 after buying an additional 86 shares in the last quarter. Finally, Ascent Group LLC lifted its position in shares of Agilent Technologies by 4.1% during the 3rd quarter. Ascent Group LLC now owns 2,209 shares of the medical research company’s stock worth $328,000 after buying an additional 87 shares during the last quarter.

Insiders Place Their Bets

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,911 shares of Agilent Technologies stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $150.00, for a total value of $286,650.00. Following the completion of the sale, the chief executive officer now directly owns 39,652 shares of the company’s stock, valued at approximately $5,947,800. The trade was a 4.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on A shares. Sanford C. Bernstein decreased their target price on Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a research report on Tuesday, November 26th. Barclays raised shares of Agilent Technologies from an “underweight” rating to an “equal weight” rating and increased their price objective for the company from $135.00 to $145.00 in a research note on Monday, February 10th. Bank of America decreased their target price on shares of Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. StockNews.com raised Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 24th. Finally, Wells Fargo & Company reduced their price objective on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating on the stock in a research report on Monday, December 9th. Seven analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $144.38.

Agilent Technologies Stock Down 0.3 %

Shares of NYSE A opened at $136.74 on Friday. The company’s 50 day moving average price is $141.04 and its 200-day moving average price is $139.28. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.58 and a current ratio of 2.09. Agilent Technologies, Inc. has a 52-week low of $124.16 and a 52-week high of $155.35. The company has a market capitalization of $39.01 billion, a P/E ratio of 30.94, a price-to-earnings-growth ratio of 3.66 and a beta of 1.07.

Agilent Technologies (NYSE:A) last released its earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.41 by $0.05. Agilent Technologies had a net margin of 19.80% and a return on equity of 25.43%. The business had revenue of $1.70 billion for the quarter, compared to analyst estimates of $1.67 billion. During the same quarter in the previous year, the business earned $1.38 earnings per share. Agilent Technologies’s revenue for the quarter was up .8% on a year-over-year basis. Equities analysts forecast that Agilent Technologies, Inc. will post 5.56 earnings per share for the current year.

Agilent Technologies Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Investors of record on Tuesday, April 1st will be paid a dividend of $0.248 per share. The ex-dividend date is Tuesday, April 1st. This represents a $0.99 annualized dividend and a yield of 0.73%. Agilent Technologies’s dividend payout ratio is currently 22.40%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.